Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market

Australian Digital health group, 1st has entered into a deal with existing client Benestar to drive adoption of an online patient platform to improve mental health.

Under the agreement, Benestar will fund the expansion of psychologists onto the MyHealth1st platform to enable faster and easier access to an external network of psychologists.

Benestar will allocate patients to external psychologists across Australia, with the future aim being for these patients to be allocated using the MyHealth1st platform.

Initial recruitment is for 2,600 psychologists and is targeted for completion by 31 July 2019.

MyHealth1st enables patients to book medical appointments online and since the induction in 2012 more than 8 million appointments have been booked on the growing 8,500 sites.

The agreement is expected to generate $1 million per year for 1st Group with further revenue possible for those who subscribe to MyHealth1st.

Managing Director and Co-Founder of 1st Group Klaus Bartosch hopes the launch will help those suffering from mental health.

“Strategic partnerships like this one with Benestar afford us with a unique opportunity to offer improved support in the mental health sector. With 20 percent of Australians suffering a mental illness each year, it is high time that we did something to help make the process much easier for patients,” he said.

Please find announcement attached here: https://hotcopper.com.au/data/pricesensitive/announcements/ASX/2A1144122_1ST.html

1ST by the numbers
More From The Market Herald
Bluechiip (ASX:BCT) - Managing Director, Andrew McLellan

" Bluechiip (ASX:BCT) to customise tech for assisted fertility market

Sample technology company Bluechiip (BCT) has signed a two-year licence and development agreement with FUJIFILM Irvine Scientific (FISI).
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) completes recruitment for Indian COVID-19 study

ResApp Health (RAP) has completed the recruitment ahead of schedule for its Indian COVID-19 clinical study.
Biogene Technology (ASX:BGT) - CEO, Richard Jagger

" Bio-Gene (ASX:BGT) shares close green on new commercial deal

Bio-Gene Technology (BGT) has executed a licence and development agreement with Evergreen Garden Care.